While the majority of patients with psoriasis initiated a pharmacological therapy, a significant portion did not have a claim for any psoriasis medication, a recent study found. Topical treatments are the most commonly used treatments for psoriasis. Non-biologic systemic and biologic therapies were rarely used first line, but became more common in later lines of treatment. Adult patients with newly-diagnosed psoriasis had continuous enrollment with medical and pharmacy benefits for ≥6 months prior to and ≥1 year following the index date, the point at which specific inclusion criteria were satisfied. Researchers found:
- From 128,308 patients identified, 53% were female, mean ± SD age was 50 ± 16 years, with median 3-year follow-up.
- Topicals were received by 86% of patients, non-biologic systemics by 13%, biologics by 6%, phototherapy by 5%, and 13% received no psoriasis-related medication.
- Median time from index to first treatment was 0 days for topical, 6 months for non-biologic systemic, and 6 months for biologic.
- Of those treated, first-line therapies included topical (95%), non-biologic systemic (4%), and biologic (2%).
- For those with second-line treatment, non-biologic systemic (71%) and biologic (30%) therapies were more common.
Murage MJ, Kern DM, Chang L, et al. Treatment patterns among patients with psoriasis using a large national payer database in the United States: A retrospective study. [Published online ahead of print October 25, 2018]. J Med Econ. doi:10.1080/13696998.2018.1540424.
This Week's Must Reads
Dermatomyositis, Negative ANA, and Malignancy Risk, J Am Acad Dermatol; ePub 2018 Nov 17; Hoesly, et al
Head/Neck Melanomas Have High Local Recurrence Risk, J Am Acad Dermatol; ePub 2018 Nov 17; Fix, et al
DOT Laser Offers Low Incidence of Adverse Effects, J Drugs Dermatol; 2018 Nov; Sarnoff, Gotkin, et al
Frontal Fibrosing Alopecia and Severity Factors , Dermatology (Karger); ePub 2018 Nov 22; Mervis, et al
Unsafe Neighborhoods Linked with Higher AD Risk, Ann Allergy Asthma Immunol; ePub 2018 Oct 26; McKenzie, et al
Must Reads in Psoriasis
Genetic Architecture of Psoriasis Explored , J Investig Dermatol Proc; 2018 Dec; Elder
Association Found Between HS and Psoriasis, J Am Acad Dermatol; ePub 2018 Nov 28; Kridin, et al
Ixekizumab Provides Rapid Improvement of Itch, Dermatolog Ther (Heidelb); ePub 2018 Dec; Yosipovitch, et al
Role of IL-17 in Psoriasis Pathogenesis Examined, Clin Rev Allerg Immunol; 2018 Dec; Blauvelt, et al
Ixekizumab: A Safe, Effective Psoriasis Treatment , J Cutan Med Surg; ePub 2018 Nov 18; Georgakopoulos, et al